Outcomes of (A-C) all patients with 11q23/KMT2A-rearranged ALL and those with (D-F) B-ALL or (G-I) T-ALL according to the type of 11q23/KMT2A rearrangement: (A, D, and G) 5-year EFS; (B, E, and H) 5-year OS; and (C, F, and I) 5-year cumulative incidence of treatment failure. 5y-pEFS, probability of 5-year event-free survival; 5y-pOS, probability of 5-year overall survival; ALL, acute lymphoblastic leukemia; EFS, event-free survival; OS, overall survival; SE, standard error.